AngioDynamics anticipates $336M-$341M FY 2027 net sales while targeting $13M-$16M adjusted EBITDA
Seeking Alpha ·
Earnings Call Insights: AngioDynamics (ANGO) Q4 FY 2026 "We capped off a year of consistent execution across the business with a strong fourth quarter. Full-year Med Tech growth of more than 18% tells the story." (CEO, President & Director James Clemmer)
AI 시장 분석
AngioDynamics projects FY2027 net sales between $336 million and $341 million, with adjusted EBITDA forecasted at $13 million to $16 million. Q4 FY2026 earnings showed strong operational execution, with the MedTech segment recording over 18% growth. Investors are focused on the company's mid-to-long-term growth guidance and the feasibility of its profitability improvement targets.
상승 영향
- Biotech — The MedTech segment has demonstrated scalability with over 18% growth. The clear 2027 revenue guidance provides improved earnings visibility, which is expected to bolster investor sentiment.
DYAX 전담 분석
The company's focus on the MedTech sector is yielding clear results, as evidenced by double-digit growth. The establishment of specific financial targets for 2027 serves to reduce uncertainty for investors. Sustained operational discipline remains key to achieving the projected EBITDA margin improvements.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 56% · Bearish (Short) 44%
363 participants